As CES 2023 draws to a close this weekend much of the attention in the chip world was lauded on companies like Advanced Micro Devices Inc. and Nvidia Corp. but a lower profile chip maker appears better positioned coming out of the convention.
Revolution Investing: No one’s having fun in the stock market these days, and that might be a sign that a bottom is near
When apathy sets in, it will be time to begin buying tech stocks again.
Earnings Watch: Banks gain favor in risk-off environment but earnings uncertainty remains
JPMorgan Chase, Wells Fargo, Citi and Bank of America are on deck to provide fourth-quarter results next Friday, while Goldman and Morgan Stanley report on Jan. 17.
: Why Luminar’s CEO is running over fake kids in a Tesla at CES
Austin Russell is trying to prove that automotive-safety systems with lidar — the technology at the core of his company — are safer than those without.
Market Extra: Financial markets ignore elephant in the room: December’s 223,000 job gains
Stocks and bonds rally in response to December jobs data showing modest wage growth, while investors look past higher-than-expected 223,000 new job gains.
Market Extra: The Dow takes ‘important first step’ toward a new bull market
Don’t dis the Dow because it only includes 30 stocks, because if the market is going to bounce back from last year’s selloff, it’ll be the Dow that leads it.
Futures Movers: Oil futures mark their first weekly loss in a month
U.S. oil futures finish modestly higher on Friday, tallying a loss of over 8% for the week after posting three consecutive weekly gains.
The Tell: History shows odds favor a 20% stock-market return in 2023 after a brutal 2022, Fundstrat says
Historical data shows there is a high chance that the U.S. stock market may record a return of 20% or more this year after the three major indexes closed 2022 with their worst annual losses since 2008, according to Fundstrat Global Advisors.
In One Chart: What China’s reopening means for markets, according to Goldman Sachs
China’s economy is set to reopen in a few days and one major Wall Street firm has boiled down the likely impact on financial markets.
: FDA approves treatment for people with mild forms of Alzheimer’s
Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year